This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Legal Alpha: Understanding the patent strength of Catalyst Pharmaceuticals’ Firdapse after Teva’s ANDA challenge
Ticker(s): CPRX, TEVAWho's the expert?
- Graduated from Georgetown Law School, after which he clerked for a Federal Judge in Chicago. Tried a number of trial cases while practicing law.
- Previously worked at Millennium Management in New York as a Portfolio Manager specializing in event-driven trading involving companies impacted by litigation, policy matters, regulatory and legislative events, and intellectual property & patent disputes.
- Advised some of the world’s leading hedge funds on trading securities impacted by legal events and catalysts, including SAC, CR Intrinsic and Millennium.
Interview GoalThis conversation is a look at our new product Legal Alpha. This subscription service focuses on analyzing the strength of intellectual property protecting key Branded Drugs, Medical Devices, and other Healthcare innovations.
This conversations focuses on the Firdapse patents and timing of a generic entrant into the market after Catalyst disclosed an ANDA filing by Teva on January 23rd.
This conversations focuses on the Firdapse patents and timing of a generic entrant into the market after Catalyst disclosed an ANDA filing by Teva on January 23rd.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
